bringing energy to life

Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease.

 

khondrion

Khondrion is a clinical-stage biopharmaceutical company discovering and developing therapies targeting mitochondrial disease. Based on proprietary science and a deep understanding of mitochondrial dysfunction, the company is advancing its wholly owned lead drug candidate sonlicromanol for the treatment of both children and adults.  

Khondrion appoints Tom Pulles, MD, as Chief Medical Officer

NIJMEGEN, the Netherlands – 1 June 2022: Khondrion (or the “Company”), a clinical stage biopharmaceutical...

Patient Perspective: A conversation with Philip Yeske, PhD – Science & Alliance Officer, UMDF

How did you first become involved with the mitochondrial disease community and the United Mitochondrial Disease...

Patient Perspective: A conversation with Alison Maguire – Head of Research & Finance, The Lily Foundation

How did you first become involved with the mitochondrial disease community and The Lily Foundation? In 2004 I became...

Patient Perspective: A conversation with Kira Mann – Newly appointed IMP Chair

How did you first become involved with the mitochondrial disease community and International Mito Patients (IMP)? I...

Khondrion completes enrollment in KHENERGYZE Phase IIb trial evaluating sonlicromanol in adult patients with MELAS spectrum disorders

NIJMEGEN, the Netherlands – 10 January 2022: Khondrion, a clinical stage biopharmaceutical company discovering and...

2021 – A Year in Review

As 2021 draws to a close, Khondrion’s CEO Jan Smeitink reflects on the past year and the continued progress...

Movement disorders in children with primary mitochondrial disease

Movement, the act or process of moving, the change of place or position or posture, is a complex process under the...

A coffee with the Scientific Advisory Board: Prof. Dr. Anu Suomalainen Wartiovaara

How did you first hear about Khondrion and the work the company is doing in mitochondrial disease? Jan Smeitink and I...

A coffee with the Scientific Advisory Board: Prof. Dr. Shamima Rahman

How did you first hear about Khondrion and the work the company is doing in mitochondrial disease? I first heard...

working with others

At Khondrion we know that working in collaboration with others is important to accelerate the development of innovative new medicines. That is why we are pursuing cutting edge science both within our own labs and through partnerships across an extensive academic and industry network of experts and are sharing knowledge around mitochondrial disease in close collaboration with patient organizations to help develop important new medicines and treatments for patients.

“the solution is within our reach”

Since 2012 Khondrion has been progressing a pipeline with the potential to deliver transformative medicines for patients living with mitochondrial disease.

get in touch

Whether you are a researcher, job seeker, health professional, patient, potential investor or potential business partner, you can contact us using this form.